Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Clinical Trial to Evaluate the Anti-Cancer Activity of the Combined Agents, Avelumab, Talazoparib and NKTR-214 and Separately Avelumab, Enzalutamide and NKTR-214

Trial Profile

A Phase 1b/2 Clinical Trial to Evaluate the Anti-Cancer Activity of the Combined Agents, Avelumab, Talazoparib and NKTR-214 and Separately Avelumab, Enzalutamide and NKTR-214

Planning
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2018

At a glance

  • Drugs Avelumab (Primary) ; Bempegaldesleukin (Primary) ; Enzalutamide (Primary) ; Talazoparib (Primary)
  • Indications Cancer; Head and neck cancer; Prostate cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top